Stifel Initiates Coverage on Olema Pharmaceuticals (OLMA) With Buy Rating

On February 11, Laura Prendergast of Stifel Nicolaus initiated sum of Olema Pharmaceuticals (NASDAQ:OLMA). She assigned a Buy standing to the banal with a $48 terms target, which leads to much than 102% upside imaginable for investors.

Pressmaster/Shutterstock.com

Using a blimpish approach, Prendergast has modeled highest income for palazestrant astatine $3.1 cardinal successful 2035. She besides noted that endocrine therapy successful ER+HER2 tin beryllium “a $20B+ planetary marketplace accidental with plentifulness of country for galore large players.”

On January 7, Michael Yee of UBS besides initiated sum of Olema Pharmaceuticals (NASDAQ:OLMA), assigning a Buy standing and a $48 terms target. He based his standing connected a much favorable outlook for the biotech conception aft what helium described arsenic a “rough period.” Yee expects greater capitalist assurance successful the segment, which should thrust amended show successful 2026.

Olema Pharmaceuticals (NASDAQ:OLMA) is simply a clinical-stage biopharmaceutical institution focused connected discovering and processing therapies for women’s cancers. They commercialize next-gen bosom crab therapies, peculiarly targeting ER+/HER2- cancer. Its pb programme is Palazestrant (OP-1250) to cure metastatic bosom cancer, which is presently successful Phase 3 objective trials.

While we admit the imaginable of OLMA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 15 Most Promising Mid-Cap Healthcare Stocks Under $50 and 11 Most Promising Small-Cap Industrial Stocks Under $50.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.